NCT03395470View on ClinicalTrials.gov

Safety, Tolerability and PK of PXL770 in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

August 21, 2017

Primary Completion Date

March 16, 2018

Study Completion Date

March 16, 2018

Conditions

Metabolic Disease

Interventions

DRUG

PXL770

MAD

DRUG

Placebo

MAD

DRUG

Rosuvastatin

DDI

Trial Locations (1)

Unknown

Hammersmith Medicines Research (HMR), London

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Poxel SA

INDUSTRY